WO2013040358A3 - Procede et compositions pour la détection d'agr2 - Google Patents

Procede et compositions pour la détection d'agr2 Download PDF

Info

Publication number
WO2013040358A3
WO2013040358A3 PCT/US2012/055416 US2012055416W WO2013040358A3 WO 2013040358 A3 WO2013040358 A3 WO 2013040358A3 US 2012055416 W US2012055416 W US 2012055416W WO 2013040358 A3 WO2013040358 A3 WO 2013040358A3
Authority
WO
WIPO (PCT)
Prior art keywords
agr2
compositions
detection
assays
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/055416
Other languages
English (en)
Other versions
WO2013040358A2 (fr
Inventor
Alvin Y. Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of WO2013040358A2 publication Critical patent/WO2013040358A2/fr
Publication of WO2013040358A3 publication Critical patent/WO2013040358A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La technologie décrite ici concerne le diagnostic, le pronostic et le traitement du cancer, par exemple, du cancer de la prostate selon les procédés et les compositions destinés à la détection d'AGR2.
PCT/US2012/055416 2011-09-14 2012-09-14 Procede et compositions pour la détection d'agr2 Ceased WO2013040358A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534791P 2011-09-14 2011-09-14
US61/534,791 2011-09-14

Publications (2)

Publication Number Publication Date
WO2013040358A2 WO2013040358A2 (fr) 2013-03-21
WO2013040358A3 true WO2013040358A3 (fr) 2013-05-10

Family

ID=47883981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055416 Ceased WO2013040358A2 (fr) 2011-09-14 2012-09-14 Procede et compositions pour la détection d'agr2

Country Status (1)

Country Link
WO (1) WO2013040358A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230340132A1 (en) * 2020-09-30 2023-10-26 Na Biotech Corp ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES
EP4274617A4 (fr) * 2021-01-05 2025-04-02 Musc Foundation for Research Development Élément de liaison bispécifique à agr2xcd3 pour le traitement du cancer
WO2022251403A1 (fr) * 2021-05-28 2022-12-01 Icahn School Of Medicine At Mount Sinai Anticorps anti-sars-cov-2 et leurs utilisations
AR128082A1 (es) * 2021-12-23 2024-03-20 Novavax Inc ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067065A2 (fr) * 2006-10-19 2008-06-05 Shiv Srivastava Procédés, kits et systèmes pour diagnostiquer et pronostiquer le cancer de la prostate en utilisant des biomarqueurs sécrétés
US7429382B2 (en) * 2002-10-16 2008-09-30 Corixa Corporation Antibodies that bind cell-associated CA 125/O772P and methods of use thereof
US20100062426A1 (en) * 2005-11-03 2010-03-11 O'hara Shawn Mark AGR2 and TFF3 Regulation in the Diagnosis and Treatment of Cancer
US20110052586A1 (en) * 2006-08-26 2011-03-03 The University Of Liverpool Antibodies to an epitope of agr2, assays and hybridomas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429382B2 (en) * 2002-10-16 2008-09-30 Corixa Corporation Antibodies that bind cell-associated CA 125/O772P and methods of use thereof
US20100062426A1 (en) * 2005-11-03 2010-03-11 O'hara Shawn Mark AGR2 and TFF3 Regulation in the Diagnosis and Treatment of Cancer
US20110052586A1 (en) * 2006-08-26 2011-03-03 The University Of Liverpool Antibodies to an epitope of agr2, assays and hybridomas
WO2008067065A2 (fr) * 2006-10-19 2008-06-05 Shiv Srivastava Procédés, kits et systèmes pour diagnostiquer et pronostiquer le cancer de la prostate en utilisant des biomarqueurs sécrétés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHANG, JIN-SAN ET AL.: "AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer", GENES CHROMOSOMES & CANCER, vol. 43, no. 3, 2005, pages 249 - 259 *
ZHANG, Y. ET AL.: "Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients", PROSTATE CANCER AND PROSTATIC DISEASES, vol. 10, no. 3, 2007, pages 293 - 300, XP008090161, DOI: doi:10.1038/sj.pcan.4500960 *

Also Published As

Publication number Publication date
WO2013040358A2 (fr) 2013-03-21

Similar Documents

Publication Publication Date Title
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2014031859A3 (fr) Compositions et méthodes se rapportant à des biomarqueurs sanguins du cancer du sein
WO2012083969A3 (fr) Microarn pour le diagnostic du cancer du pancréas
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
WO2012021887A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
WO2011153254A3 (fr) Biomarqueurs d'acides nucléiques circulants associés au cancer de la prostate
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2012106718A3 (fr) Procédés d'utilisation de signatures d'expression génique pour sélectionner un procédé de traitement, prédire un pronostic, la survie, et/ou prédire une réponse à un traitement
WO2012047618A3 (fr) Biomarqueurs de mésothéliome et utilisations de ceux-ci
HK1197273A1 (en) Methods and materials related to ovarian cancer
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
WO2012154983A3 (fr) Systèmes et procédés pour des anticorps anti-pax8
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
MX2015001433A (es) Aptameros cd133 para deteccion de celulas madre cancerosas.
WO2011112845A3 (fr) Méthodes et compositions associés à un essai de méthylation multiple pour prédire l'évolution de l'état de santé d'un patient
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
WO2013124738A3 (fr) Méthodes et biomarqueurs permettant de dépister et de pronostiquer le cancer du col utérin
WO2014197835A3 (fr) Méthodes et compositions pour le traitement du cancer
WO2013082249A3 (fr) Compositions et procédés pour l'analyse du cancer de la prostate
WO2013052108A3 (fr) Méthodes et compositions destinées à traiter et à diagnostiquer un cancer de l'ovaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832362

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12832362

Country of ref document: EP

Kind code of ref document: A2